• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Study on the Molecular Mechanism of the Herbal Couple Sparganii Rhizoma-Curcumae Rhizoma in the Treatment of Lung Cancer Based on Network Pharmacology
【24h】

Study on the Molecular Mechanism of the Herbal Couple Sparganii Rhizoma-Curcumae Rhizoma in the Treatment of Lung Cancer Based on Network Pharmacology

机译：草药综合斯普林氏植物莪术 - 莪术治疗基于网络药理学治疗肺癌的分子机制研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background . Lung cancer has a poor prognosis and a high mortality rate, and patients may develop multidrug resistance. Sparganii Rhizoma-Curcumae Rhizoma (HCSC), the classic herbal drug combination of traditional Chinese medicine (TCM), is commonly used in treating tumors, but its molecular mechanism is still unclear. Method . We explored the possible mechanisms underlying the antitumor effect of HCSC using network pharmacology. The bioactive components of HCSC and their targets were collected from the TCM Systems Pharmacology (TCMSP) database and PharmMapper. Gene Ontology (GO) and KEGG enrichment analyses were performed; the GeneMANIA platform was used for the functional enrichment analysis of the core targets and their neighboring genes. Molecular docking was performed between the bioactive components and core targets. HCSC freeze-dried powder was prepared, and the bioactive components were verified by liquid chromatography- (LC-) mass spectrometry (MS). Human lung adenocarcinoma H1975 cells were cultured to verify in vitro the molecular mechanism of action of HCSC in treating lung cancer, as predicted by network pharmacology. Finally, we used the Symmap database to predict the relationship between the herb and TCM syndrome. Result . A total of seven bioactive components were identified by network pharmacological analysis. Through enrichment analyses, it was found that the mechanism of action mainly involved mitochondrial-mediated caspase-dependent cell apoptosis signaling pathways. The results of molecular docking showed that the bioactive components in HCSC have a good affinity with the target proteins (ALB, BCL2L1, ESR1, HRAS, MAP2K1, MAPK14, and SIRT1). LC-MS confirmed that formononetin and bisdemethoxycurcumin were present in the HCSC freeze-dried powder, consistent with the prediction. The results of in vitro experiments on NCI-H1975 cells confirmed that HCSC can upregulate the mitochondrial-mediated caspase-dependent apoptosis signaling pathway by inducing the cleavage of caspase-3, caspase-9, and PARP, consistent with the network pharmacology prediction. Further, the qi deficiency and blood stasis associated with TCM syndrome can be treated with HCSC.
机译：背景 。肺癌预后差和高死亡率，患者可能会产生多药抗性。 Spargaii Rhizoma-Curcumae Rhizoma（HCSC），中药经典草药组合（TCM），通常用于治疗肿瘤，但其分子机制尚不清楚。方法 。我们探讨了使用网络药理学抗询问HCSC抗肿瘤效应的可能机制。从中医系统药理（TCMSP）数据库和药物涂布器中收集HCSC的生物活性组分及其靶标。进行基因本体（GO）和KEGG富集分析; Genemania平台用于核心目标和邻近基因的功能性浓缩分析。在生物活性成分和核心靶标之间进行分子对接。制备HCSC冷冻干燥的粉末，通过液相色谱 - （LC-）质谱（MS）验证生物活性组分。培养人肺腺癌H1975细胞以验证HCSC治疗肺癌治疗肺癌的分子机制，如网络药理学预测。最后，我们使用Symmap数据库预测草草和中医综合征之间的关系。结果 。通过网络药理学分析鉴定了总共七种生物活性组分。通过富集分析，发现作用机制主要涉及线粒体介导的胱依赖性细胞凋亡信号通路。分子对接的结果表明，HCSC中的生物活性成分与靶蛋白（ALB，BCL2L1，ESR1，HRAS，MAP2K1，MAPK14和SIRT1具有良好的亲和力。 LC-MS证实，与预测一致的HCSC冷冻干燥的粉末中存在甲酰键和双甲氧键菌蛋白。 NCI-H1975细胞体外实验结果证实，HCSC通过诱导与网络药理学预测一致的Caspase-3，Caspase-9和PARP的切割来上调线粒体介导的胱级依赖性凋亡信号通路。此外，可以用HCSC治疗与TCM综合征相关的QI缺乏和血瘀。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号